private:navitorpharmaceuticals
|
5238741
|
Dec 3rd, 2020 12:00AM
|
Navitor Pharmaceuticals
|
1.8K
|
21.00
|
Open
|
Biotechnology
|
Dec 3rd, 2020 11:53AM
|
Dec 3rd, 2020 11:53AM
|
Navitor Pharmaceuticals, Inc., is a biopharmaceutical company developing novel medicines by targeting cellular nutrient signaling pathways. The company’s proprietary drug discovery platform targets mTORC1, which responds to and integrates the cell’s response to nutrient availability and plays a key role in protein synthesis and cellular growth. Navitor’s therapeutics are designed to selectively modulate the cellular signals that are aberrant in disease processes caused by the dysregulation of mTORC1 activity to address a wide range of diseases, including metabolic, neurodegenerative, autoimmune and musculoskeletal diseases, as well as several rare disorders. The company’s founding intellectual property is based on the groundbreaking discoveries related to the mTORC1 pathway and nutrient signaling mechanisms by Dr. David Sabatini at The Whitehead Institute for Biomedical Research. The company is backed by leading financial and corporate investors, including Polaris Partners, Atlas Venture, Johnson & Johnson Development Corporation, SR One and The Longevity Fund.
|
Open
|
|
Open
|
1030 Massachusetts Ave, Suite 410
|
Cambridge
|
MA
|
US
|
02139
|
|
Navitor Pharmaceuticals
|
Oil & Gas
|
Health Care Equipment & Services
|
private:navitorpharmaceuticals
|
5238741
|
Dec 2nd, 2020 12:00AM
|
Navitor Pharmaceuticals
|
1.8K
|
21.00
|
Open
|
Biotechnology
|
Dec 2nd, 2020 02:13PM
|
Dec 2nd, 2020 02:13PM
|
Navitor Pharmaceuticals, Inc., is a biopharmaceutical company developing novel medicines by targeting cellular nutrient signaling pathways. The company’s proprietary drug discovery platform targets mTORC1, which responds to and integrates the cell’s response to nutrient availability and plays a key role in protein synthesis and cellular growth. Navitor’s therapeutics are designed to selectively modulate the cellular signals that are aberrant in disease processes caused by the dysregulation of mTORC1 activity to address a wide range of diseases, including metabolic, neurodegenerative, autoimmune and musculoskeletal diseases, as well as several rare disorders. The company’s founding intellectual property is based on the groundbreaking discoveries related to the mTORC1 pathway and nutrient signaling mechanisms by Dr. David Sabatini at The Whitehead Institute for Biomedical Research. The company is backed by leading financial and corporate investors, including Polaris Partners, Atlas Venture, Johnson & Johnson Development Corporation, SR One and The Longevity Fund.
|
Open
|
|
Open
|
1030 Massachusetts Ave, Suite 410
|
Cambridge
|
MA
|
US
|
02139
|
|
Navitor Pharmaceuticals
|
Oil & Gas
|
Health Care Equipment & Services
|
private:navitorpharmaceuticals
|
5238741
|
Dec 1st, 2020 12:00AM
|
Navitor Pharmaceuticals
|
1.8K
|
21.00
|
Open
|
Biotechnology
|
Dec 1st, 2020 01:43PM
|
Dec 1st, 2020 01:43PM
|
Navitor Pharmaceuticals, Inc., is a biopharmaceutical company developing novel medicines by targeting cellular nutrient signaling pathways. The company’s proprietary drug discovery platform targets mTORC1, which responds to and integrates the cell’s response to nutrient availability and plays a key role in protein synthesis and cellular growth. Navitor’s therapeutics are designed to selectively modulate the cellular signals that are aberrant in disease processes caused by the dysregulation of mTORC1 activity to address a wide range of diseases, including metabolic, neurodegenerative, autoimmune and musculoskeletal diseases, as well as several rare disorders. The company’s founding intellectual property is based on the groundbreaking discoveries related to the mTORC1 pathway and nutrient signaling mechanisms by Dr. David Sabatini at The Whitehead Institute for Biomedical Research. The company is backed by leading financial and corporate investors, including Polaris Partners, Atlas Venture, Johnson & Johnson Development Corporation, SR One and The Longevity Fund.
|
Open
|
|
Open
|
1030 Massachusetts Ave, Suite 410
|
Cambridge
|
MA
|
US
|
02139
|
|
Navitor Pharmaceuticals
|
Oil & Gas
|
Health Care Equipment & Services
|
private:navitorpharmaceuticals
|
5238741
|
Nov 30th, 2020 12:00AM
|
Navitor Pharmaceuticals
|
1.8K
|
21.00
|
Open
|
Biotechnology
|
Nov 29th, 2020 07:47PM
|
Nov 30th, 2020 02:35PM
|
Navitor Pharmaceuticals, Inc., is a biopharmaceutical company developing novel medicines by targeting cellular nutrient signaling pathways. The company’s proprietary drug discovery platform targets mTORC1, which responds to and integrates the cell’s response to nutrient availability and plays a key role in protein synthesis and cellular growth. Navitor’s therapeutics are designed to selectively modulate the cellular signals that are aberrant in disease processes caused by the dysregulation of mTORC1 activity to address a wide range of diseases, including metabolic, neurodegenerative, autoimmune and musculoskeletal diseases, as well as several rare disorders. The company’s founding intellectual property is based on the groundbreaking discoveries related to the mTORC1 pathway and nutrient signaling mechanisms by Dr. David Sabatini at The Whitehead Institute for Biomedical Research. The company is backed by leading financial and corporate investors, including Polaris Partners, Atlas Venture, Johnson & Johnson Development Corporation, SR One and The Longevity Fund.
|
Open
|
|
Open
|
1030 Massachusetts Ave, Suite 410
|
Cambridge
|
MA
|
US
|
02139
|
|
Navitor Pharmaceuticals
|
Oil & Gas
|
Health Care Equipment & Services
|
private:navitorpharmaceuticals
|
5238741
|
Nov 28th, 2020 12:00AM
|
Navitor Pharmaceuticals
|
1.8K
|
21.00
|
Open
|
Biotechnology
|
Nov 28th, 2020 03:23PM
|
Nov 28th, 2020 03:23PM
|
Navitor Pharmaceuticals, Inc., is a biopharmaceutical company developing novel medicines by targeting cellular nutrient signaling pathways. The company’s proprietary drug discovery platform targets mTORC1, which responds to and integrates the cell’s response to nutrient availability and plays a key role in protein synthesis and cellular growth. Navitor’s therapeutics are designed to selectively modulate the cellular signals that are aberrant in disease processes caused by the dysregulation of mTORC1 activity to address a wide range of diseases, including metabolic, neurodegenerative, autoimmune and musculoskeletal diseases, as well as several rare disorders. The company’s founding intellectual property is based on the groundbreaking discoveries related to the mTORC1 pathway and nutrient signaling mechanisms by Dr. David Sabatini at The Whitehead Institute for Biomedical Research. The company is backed by leading financial and corporate investors, including Polaris Partners, Atlas Venture, Johnson & Johnson Development Corporation, SR One and The Longevity Fund.
|
Open
|
|
Open
|
1030 Massachusetts Ave, Suite 410
|
Cambridge
|
MA
|
US
|
02139
|
|
Navitor Pharmaceuticals
|
Oil & Gas
|
Health Care Equipment & Services
|
private:navitorpharmaceuticals
|
5238741
|
Nov 27th, 2020 12:00AM
|
Navitor Pharmaceuticals
|
1.8K
|
21.00
|
Open
|
Biotechnology
|
Nov 27th, 2020 11:48AM
|
Nov 27th, 2020 11:48AM
|
Navitor Pharmaceuticals, Inc., is a biopharmaceutical company developing novel medicines by targeting cellular nutrient signaling pathways. The company’s proprietary drug discovery platform targets mTORC1, which responds to and integrates the cell’s response to nutrient availability and plays a key role in protein synthesis and cellular growth. Navitor’s therapeutics are designed to selectively modulate the cellular signals that are aberrant in disease processes caused by the dysregulation of mTORC1 activity to address a wide range of diseases, including metabolic, neurodegenerative, autoimmune and musculoskeletal diseases, as well as several rare disorders. The company’s founding intellectual property is based on the groundbreaking discoveries related to the mTORC1 pathway and nutrient signaling mechanisms by Dr. David Sabatini at The Whitehead Institute for Biomedical Research. The company is backed by leading financial and corporate investors, including Polaris Partners, Atlas Venture, Johnson & Johnson Development Corporation, SR One and The Longevity Fund.
|
Open
|
|
Open
|
1030 Massachusetts Ave, Suite 410
|
Cambridge
|
MA
|
US
|
02139
|
|
Navitor Pharmaceuticals
|
Oil & Gas
|
Health Care Equipment & Services
|
private:navitorpharmaceuticals
|
5238741
|
Nov 26th, 2020 12:00AM
|
Navitor Pharmaceuticals
|
1.8K
|
21.00
|
Open
|
Biotechnology
|
Nov 26th, 2020 12:46PM
|
Nov 26th, 2020 12:46PM
|
Navitor Pharmaceuticals, Inc., is a biopharmaceutical company developing novel medicines by targeting cellular nutrient signaling pathways. The company’s proprietary drug discovery platform targets mTORC1, which responds to and integrates the cell’s response to nutrient availability and plays a key role in protein synthesis and cellular growth. Navitor’s therapeutics are designed to selectively modulate the cellular signals that are aberrant in disease processes caused by the dysregulation of mTORC1 activity to address a wide range of diseases, including metabolic, neurodegenerative, autoimmune and musculoskeletal diseases, as well as several rare disorders. The company’s founding intellectual property is based on the groundbreaking discoveries related to the mTORC1 pathway and nutrient signaling mechanisms by Dr. David Sabatini at The Whitehead Institute for Biomedical Research. The company is backed by leading financial and corporate investors, including Polaris Partners, Atlas Venture, Johnson & Johnson Development Corporation, SR One and The Longevity Fund.
|
Open
|
|
Open
|
1030 Massachusetts Ave, Suite 410
|
Cambridge
|
MA
|
US
|
02139
|
|
Navitor Pharmaceuticals
|
Oil & Gas
|
Health Care Equipment & Services
|
private:navitorpharmaceuticals
|
5238741
|
Nov 25th, 2020 12:00AM
|
Navitor Pharmaceuticals
|
1.8K
|
21.00
|
Open
|
Biotechnology
|
Nov 25th, 2020 06:17PM
|
Nov 25th, 2020 06:17PM
|
Navitor Pharmaceuticals, Inc., is a biopharmaceutical company developing novel medicines by targeting cellular nutrient signaling pathways. The company’s proprietary drug discovery platform targets mTORC1, which responds to and integrates the cell’s response to nutrient availability and plays a key role in protein synthesis and cellular growth. Navitor’s therapeutics are designed to selectively modulate the cellular signals that are aberrant in disease processes caused by the dysregulation of mTORC1 activity to address a wide range of diseases, including metabolic, neurodegenerative, autoimmune and musculoskeletal diseases, as well as several rare disorders. The company’s founding intellectual property is based on the groundbreaking discoveries related to the mTORC1 pathway and nutrient signaling mechanisms by Dr. David Sabatini at The Whitehead Institute for Biomedical Research. The company is backed by leading financial and corporate investors, including Polaris Partners, Atlas Venture, Johnson & Johnson Development Corporation, SR One and The Longevity Fund.
|
Open
|
|
Open
|
1030 Massachusetts Ave, Suite 410
|
Cambridge
|
MA
|
US
|
02139
|
|
Navitor Pharmaceuticals
|
Oil & Gas
|
Health Care Equipment & Services
|
private:navitorpharmaceuticals
|
5238741
|
Nov 24th, 2020 12:00AM
|
Navitor Pharmaceuticals
|
1.8K
|
21.00
|
Open
|
Biotechnology
|
Nov 24th, 2020 01:35PM
|
Nov 24th, 2020 01:35PM
|
Navitor Pharmaceuticals, Inc., is a biopharmaceutical company developing novel medicines by targeting cellular nutrient signaling pathways. The company’s proprietary drug discovery platform targets mTORC1, which responds to and integrates the cell’s response to nutrient availability and plays a key role in protein synthesis and cellular growth. Navitor’s therapeutics are designed to selectively modulate the cellular signals that are aberrant in disease processes caused by the dysregulation of mTORC1 activity to address a wide range of diseases, including metabolic, neurodegenerative, autoimmune and musculoskeletal diseases, as well as several rare disorders. The company’s founding intellectual property is based on the groundbreaking discoveries related to the mTORC1 pathway and nutrient signaling mechanisms by Dr. David Sabatini at The Whitehead Institute for Biomedical Research. The company is backed by leading financial and corporate investors, including Polaris Partners, Atlas Venture, Johnson & Johnson Development Corporation, SR One and The Longevity Fund.
|
Open
|
|
Open
|
1030 Massachusetts Ave, Suite 410
|
Cambridge
|
MA
|
US
|
02139
|
|
Navitor Pharmaceuticals
|
Oil & Gas
|
Health Care Equipment & Services
|
private:navitorpharmaceuticals
|
5238741
|
Nov 23rd, 2020 12:00AM
|
Navitor Pharmaceuticals
|
1.8K
|
21.00
|
Open
|
Biotechnology
|
Nov 23rd, 2020 03:36PM
|
Nov 23rd, 2020 03:36PM
|
Navitor Pharmaceuticals, Inc., is a biopharmaceutical company developing novel medicines by targeting cellular nutrient signaling pathways. The company’s proprietary drug discovery platform targets mTORC1, which responds to and integrates the cell’s response to nutrient availability and plays a key role in protein synthesis and cellular growth. Navitor’s therapeutics are designed to selectively modulate the cellular signals that are aberrant in disease processes caused by the dysregulation of mTORC1 activity to address a wide range of diseases, including metabolic, neurodegenerative, autoimmune and musculoskeletal diseases, as well as several rare disorders. The company’s founding intellectual property is based on the groundbreaking discoveries related to the mTORC1 pathway and nutrient signaling mechanisms by Dr. David Sabatini at The Whitehead Institute for Biomedical Research. The company is backed by leading financial and corporate investors, including Polaris Partners, Atlas Venture, Johnson & Johnson Development Corporation, SR One and The Longevity Fund.
|
Open
|
|
Open
|
1030 Massachusetts Ave, Suite 410
|
Cambridge
|
MA
|
US
|
02139
|
|
Navitor Pharmaceuticals
|
Oil & Gas
|
Health Care Equipment & Services
|